Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344478 | 0.93 | KMT2A (0.52) | KMT2AGPR34MAOAMAOBACHE | |
| SCHEMBL3500353 | 0.93 | KMT2A (0.52) | KMT2AGPR34MAOAMAOBACHE | |
| SCHEMBL3498698 | 0.89 | GPR34 (0.54) | KMT2ACDK2GPR34MAOAMAOB | |
| SCHEMBL3499082 | 0.89 | GPR34 (0.54) | KMT2ACDK2GPR34MAOAMAOB | |
| SCHEMBL3498602 | 0.88 | KMT2A (0.46) | KMT2ACDK2GPR34MAOAMAOB | |
| SCHEMBL3498606 | 0.88 | KMT2A (0.46) | KMT2ACDK2GPR34MAOAMAOB | |
| SCHEMBL3497794 | 0.87 | KMT2A (0.44) | KMT2ACDK2GPR34HDAC1HDAC6 | |
| SCHEMBL5268802 | 0.83 | GPR34 (0.54) | KMT2ACDK2GPR34PPARGMMP13 | |
| SCHEMBL3504494 | 0.83 | CAPN1 (0.49) | KMT2ACDK2HDAC1HDAC6MEN1 | |
| SCHEMBL3504496 | 0.83 | CAPN1 (0.49) | KMT2ACDK2HDAC1HDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | KMT2A 2910/4885CDK2 2075/4885GPR34 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.